Oppenheimer Maintains Outperform on Tarsus Pharmaceuticals, Raises Price Target to $100
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.
Oppenheimer analyst Francois Brisebois maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and raises the price target from $97 to $100.